Gary D. Myers

Hematology | Oncology

262 Danny Thomas Pl
Memphis, TN 38105

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.

Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 29, 2026

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

Journal: Blood advances

Published: March 24, 2026

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.

Journal: Blood advances

Published: April 29, 2025

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.

Journal: Blood advances

Published: April 14, 2025

Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.

Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL.

Journal: Blood advances

Published: November 18, 2024

Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.

Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.

Journal: Blood advances

Published: September 29, 2023

Target Aortic Stenosis: A National Initiative to Improve Quality of Care and Outcomes for Patients With Aortic Stenosis.

Target Aortic Stenosis: A National Initiative to Improve Quality of Care and Outcomes for Patients With Aortic Stenosis.

Journal: Circulation. Cardiovascular quality and outcomes

Published: June 20, 2023

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.

Journal: EClinicalMedicine

Published: March 13, 2023

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 18, 2022

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 15, 2022

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.

Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.

Journal: Blood advances

Published: February 04, 2022

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 09, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026